Patient-centered care: Key elements applicable to chronic liver disease.
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
01 07 2023
01 07 2023
Historique:
received:
09
04
2022
accepted:
09
06
2022
medline:
21
6
2023
pubmed:
18
6
2022
entrez:
17
6
2022
Statut:
ppublish
Résumé
Chronic liver disease (CLD) is a progressive illness with high symptom burden and functional and cognitive impairment, often with comorbid mental and substance use disorders. These factors lead to significant deterioration in quality of life, with immense burden on patients, caregivers, and healthcare. The current healthcare system in the United States does not adequately meet the needs of patients with CLD or control costs given the episodic, reactive, and fee-for-service structure. There is also a need for clinical and financial accountability for CLD care. In this context, we describe the key elements required to shift the CLD care paradigm to a patient-centered and value-based system built upon the Porter model of value-based health care. The key elements include (1) organization into integrated practice units, (2) measuring and incorporating meaningful patient-reported outcomes, (3) enabling technology to allow innovation, (4) bundled care payments, (5) integrating palliative care within routine care, and (6) formalizing centers of excellence. These elements have been shown to improve outcomes, reduce costs, and improve overall patient experience for other chronic illnesses and should have similar benefits for CLD. Payers need to partner with providers and systems to build upon these elements and help align reimbursements with patients' values and outcomes. The national organizations such as the American Association for Study of Liver Diseases need to guide key stakeholders in standardizing these elements to optimize patient-centered care for CLD.
Identifiants
pubmed: 35712801
pii: 01515467-202307000-00025
doi: 10.1002/hep.32618
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
307-318Informations de copyright
Copyright © 2023 American Association for the Study of Liver Diseases.
Références
Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151–71.
Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol. 2020;18(12):2650–66.
Williams R, Alexander G, Aspinall R, Bosanquet J, Camps‐Walsh G, Cramp M, et al. New metrics for the Lancet standing commission on liver disease in the UK. Lancet. 2017;389(10083):2053–80.
Bianchi G, Marchesini G, Nicolino F, Graziani R, Sgarbi D, Loguercio C, et al. Psychological status and depression in patients with liver cirrhosis. Dig Liver Dis. 2005;37(8):593–600.
Volk ML, Tocco RS, Bazick J, Rakoski MO, Lok AS. Hospital re‐admissions among patients with decompensated cirrhosis. Am J Gastroenterol. 2012;107(2):247–52.
Peng JK, Hepgul N, Higginson IJ, Gao W. Symptom prevalence and quality of life of patients with end‐stage liver disease: a systematic review and meta‐analysis. Palliat Med. 2019;33(1):24–36.
D'Amico G, Garcia‐Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–31.
Kelly EM, James PD, Murthy S, Antonova L, Wong F, Shaw‐Stiffel T, et al. Health care utilization and costs for patients with end‐stage liver disease are significantly higher at the end of life compared to those of other decedents. Clin Gastroenterol Hepatol. 2019;17(11):2339–46.e1.
Mellinger JL, Moser S, Welsh DE, Yosef MT, Van T, McCurdy H, et al. Access to subspecialty care and survival among patients with liver disease. Am J Gastroenterol. 2016;111(6):838–44.
Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. Washington, DC: National Academies Press; 2001.
Baumhauer JF, Bozic KJ. Value‐based healthcare: patient‐reported outcomes in clinical decision making. Clin Orthop Relat Res. 2016;474(6):1375–8.
What is value‐based healthcare? NEJM Catalyst [Internet]. 2017 Jan; 3(1). [cited 2022 Apr 4]. Available from: https://catalyst.nejm.org/doi/full/10.1056/CAT.17.0558
doi: https://catalyst.nejm.org/doi/full/10.1056/CAT.17.0558
Ma C, Qian AS, Nguyen NH, Stukalin I, Congly SE, Swain MG, et al. Trends in the economic burden of chronic liver diseases and cirrhosis in the United States: 1996–2016. Am J Gastroenterol. 2021;116:2060–7.
Lago‐Hernandez C, Nguyen NH, Khera R, Loomba R, Asrani SK, Singh S. Financial hardship from medical bills among adults with chronic liver diseases: national estimates from the United States. Hepatology. 2021;74:1509–22.
Porter ME. Value‐based healthcare delivery. 2014 Jan [cited 2021 Apr 13]. Available from: https://www.hbs.edu/ris/Publication%20Files/3_13615129‐eeec‐4987‐bf1a‐1261ff86ae69.pdf
Porter ME. A strategy for health care reform—toward a value‐based system. N Engl J Med. 2009;361(2):109–12.
Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672–82.
Gordon SC, Fraysse J, Li S, Ozbay AB, Wong RJ. Disease severity is associated with higher healthcare utilization in nonalcoholic steatohepatitis medicare patients. Am J Gastroenterol. 2020;115(4):562–74.
Younossi ZM, Corey KE, Alkhouri N, Noureddin M, Jacobson I, Lam B, et al. Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices. Aliment Pharmacol Ther. 2020;52(3):513–26.
Noureddin M, Jones C, Alkhouri N, Gomez EV, Dieterich DT, Rinella ME, et al. Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost‐effective: a comprehensive cost‐utility analysis. Gastroenterology. 2020;159(5):1985–7.e4.
Puri P, Fuchs M. Population management of nonalcoholic fatty liver disease. Fed Pract. 2019;36(2):72–82.
Valery PC, Powell EE. Engaging primary care clinicians in the assessment of NAFLD. Nat Rev Gastroenterol Hepatol. 2019;16(8):458–60.
Canbay A, Kälsch J, Neumann U, Rau M, Hohenester S, Baba HA, et al. Non‐invasive assessment of NAFLD as systemic disease—a machine learning perspective. PloS One. 2019;14(3):e0214436.
Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104–12.
Castera L, Friedrich‐Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(5):1264–81.e4.
Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wong VWS, Wright E, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161(5):1657–69.
Serper M, Taddei TH, Mehta R, D'Addeo K, Dai F, Aytaman A, et al. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. Gastroenterology. 2017;152(8):1954–64.
Kanwal F, Asch SM, Kramer JR, Cao Y, Asrani S, El‐Serag HB. Early outpatient follow‐up and 30‐day outcomes in patients hospitalized with cirrhosis. Hepatology. 2016;64(2):569–81.
Hernaez R, Kanwal F. Leveraging telemedicine for quality assessment. Clin Liver Dis. 2022;19(4):176–80.
Basch E, Barbera L, Kerrigan CL, Velikova G. Implementation of patient‐reported outcomes in routine medical care. Am Soc Clin Oncol Educ Book. 2018;38:122–34.
Verma M, Younossi Z. Integrating patient reported outcomes within routine hepatology care: a prompt to action. Hepatology. 2021;73:1570–80.
Verma M. Patient reported outcomes as emerging biomarkers in chronic liver disease research. J Hepatol. 2020;72(6):1215–6.
Food and Drug Administration. Patient‐reported outcomes (PROs) in medical device decision making. 2019. [cited 2020 Dec 25]. Available from: https://www.fda.gov/about‐fda/cdrh‐patient‐engagement/patient‐reported‐outcomes‐pros‐medical‐device‐decision‐making
Basch E, Abernethy AP. Supporting clinical practice decisions with real‐time patient‐reported outcomes. J Clin Oncol. 2011;29(8):954–6.
Verma M, Navarro V. Patient‐centered care: a new paradigm for chronic liver disease. Hepatology. 2015;62(4):988–90.
National Quality Forum. Patient reported outcomes (PROs) in performance measurement. Washington, DC: National Quality Forum; 2013.
Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, et al. Overall survival results of a trial assessing patient‐reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017;318(2):197–8.
Howell D, Molloy S, Wilkinson K, Green E, Orchard K, Wang K, et al. Patient‐reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Ann Oncol. 2015;26:1846–58.
Opipari‐Arrigan L, Dykes DM, Saeed SA, Thakkar S, Burns L, Chini BA, et al. Technology‐enabled health care collaboration in pediatric chronic illness: pre‐post interventional study for feasibility, acceptability, and clinical impact of an electronic health record–linked platform for patient‐clinician partnership. JMIR Mhealth Uhealth. 2020;8(11):e11968.
Verma M, Stites S, Navarro V. Bringing assessment of patient‐reported outcomes to hepatology practice. Clin Gastroenterol Hepatol. 2018;16(3):447–8.
Kanwal F, Tapper EB, Ho C, Asrani SK, Ovchinsky N, Poterucha J, et al. Development of quality measures in cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology. 2019;69(4):1787–97.
Asrani SK, Ghabril MS, Kuo A, Merriman RB, Morgan T, Parikh ND, et al. Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology. 2022;75(5):1289–99.
Volk ML, Clarke C, Asrani SK, Khaderi S, Bansal MB, Tapper EB, et al. Cirrhosis Quality Collaborative. Clin Gastroenterol Hepatol. 2022;20(5):970–2.
Holmgren AJ, Adler‐Milstein J. Health information exchange in US hospitals: the current landscape and a path to improved information sharing. J Hosp Med. 2017;12(3):193–8.
Verma M, Chan M, Toroghi HM, Gallagher M, Gholami S, Lo K, et al. Multimedia patient education led to improvement in disease knowledge among patients with chronic liver diseases. Hepatology. 2021;74(S1):Abstract 651A.
Cirrhosis Care. [cited 2020 Jun 6]. Available from: https://cirrhosiscare.ca/
Shearer JE, Gonzalez JJ, Min T, Parker R, Jones R, Su GL, et al. Systematic review: development of a consensus code set to identify cirrhosis in electronic health records. Aliment Pharmacol Ther. 2022;55(6):645–57.
Driver RJ, Balachandrakumar V, Burton A, Shearer J, Downing A, Cross T, et al. Validation of an algorithm using inpatient electronic health records to determine the presence and severity of cirrhosis in patients with hepatocellular carcinoma in England: an observational study. BMJ Open. 2019;9(7):e028571.
Hagström H, Adams LA, Allen AM, Byrne CD, Chang Y, Grønbæk H, et al. Administrative coding in electronic health care record‐based research of NAFLD: an expert panel consensus statement. Hepatology. 2021;74(1):474–82.
Van Vleck TT, Chan L, Coca SG, Craven CK, Do R, Ellis SB, et al. Augmented intelligence with natural language processing applied to electronic health records for identifying patients with non‐alcoholic fatty liver disease at risk for disease progression. Int J Med Inform. 2019;129:334–41.
Kumar R, Khan FU, Sharma A, Aziz I, Poddar NK. Recent applications of artificial intelligence in the detection of gastrointestinal, hepatic and pancreatic diseases. Curr Med Chem. 2022;29(1):66–85.
Wigg AJ, McCormick R, Wundke R, Woodman RJ. Efficacy of a chronic disease management model for patients with chronic liver failure. Clin Gastroenterol Hepatol. 2013;11(7):850–8.e4.
Japinga M, Saunders R, Gellad ZF, McClellan M. The evolving payment reform landscape: new opportunities for gastroenterology leadership. Clin Gastroenterol Hepatol. 2017;15(9):1322–5.
CMS. MACRA: MIPS & APMs. 2018. [cited 2022 Apr 19]. Available from: https://www.cms.gov/Medicare/Quality‐Initiatives‐Patient‐Assessment‐Instruments/Value‐Based‐Programs/MACRA‐MIPS‐and‐APMs/MACRA‐MIPS‐and‐APMs.html
Patel K, Presser E, George M, McClellan M. Shifting away from fee‐for‐service: alternative approaches to payment in gastroenterology. Clin Gastroenterol Hepatol. 2016;14(4):497–506.
Smith TJ, Temin S, Alesi ER, Abernethy AP, Balboni TA, Basch EM, et al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol. 2012;30(8):880–7.
Verma M, Tapper EB, Singal AG, Navarro V. Nonhospice palliative care within the treatment of end‐stage liver disease. Hepatology. 2020;71(6):2149–59.
Rush B, Walley KR, Celi LA, Rajoriya N, Brahmania M. Palliative care access for hospitalized patients with end‐stage liver disease across the United States. Hepatology. 2017;66(5):1585–91.
Institute of Medicine (IOM). Dying in America: improving quality and honoring individual preferences near the end of life. Washington, DC: The National Academies Press; 2015.
Verma M, Kosinski AS, Volk ML, Taddei T, Ramchandran K, Bakitas M, et al. Introducing palliative care within the treatment of end‐stage liver disease: the study protocol of a cluster randomized controlled trial. J Palliat Med. 2019;22(S1):34–43.
DeNofrio JC, Verma M, Kosinski AS, Navarro V, Taddei TH, Volk ML, et al. Palliative care always: hepatology—virtual primary palliative care training for hepatologists. Hepatol Communi. 2022;6(4):920–30.
Tapper EB, Asrani SK. The COVID‐19 pandemic will have a long‐lasting impact on the quality of cirrhosis care. J Hepatol. 2020;73(2):441–5.
Serper M, Nunes F, Ahmad N, Roberts D, Metz DC, Mehta SJ. Positive early patient and clinician experience with telemedicine in an academic gastroenterology practice during the COVID‐19 pandemic. Gastroenterology. 2020;159(4):1589–91.e4.
Serper M, Cubell AW, Deleener ME, Casher TK, Rosenberg DJ, Whitebloom D, et al. Telemedicine in liver disease and beyond: can the COVID‐19 crisis lead to action? Hepatology. 2020;72(2):723–8.
Mahmud N, Hubbard RA, Kaplan DE, Serper M. Declining cirrhosis hospitalizations in the wake of the COVID‐19 pandemic: a national cohort study. Gastroenterology. 2020;159(3):1134–6.e3.
Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364(23):2199–207.
Su LN, Guo SL, Li BX, Yang P. Diagnostic value of magnetic resonance elastography for detecting and staging of hepatic fibrosis: a meta‐analysis. Clin Radiol. 2014;69(12):e545–52.
John BV, Love E, Dahman B, Kurbanova N, Konjeti VR, Sundaram LT, et al. Use of telehealth expedites evaluation and listing of patients referred for liver transplantation. Clin Gastroenterol Hepatol. 2020;18(8):1822–30.e4.
Allampati S, Duarte‐Rojo A, Thacker LR, Patidar KR, White MB, Klair JS, et al. Diagnosis of minimal hepatic encephalopathy using Stroop EncephalApp: a multicenter US‐based, norm‐based study. Am J Gastroenterol. 2016;111(1):78–86.
Bajaj JS, Heuman DM, Sterling RK, Sanyal AJ, Siddiqui M, Matherly S, et al. Validation of EncephalApp, smartphone‐based Stroop test, for the diagnosis of covert hepatic encephalopathy. Clin Gastroenterol Hepatol. 2015;13(10):1828–35.e1.
Jansen C, Chatterjee DA, Thomsen KL, Al‐Kassou B, Sawhney R, Jones H, et al. Significant reduction in heart rate variability is a feature of acute decompensation of cirrhosis and predicts 90‐day mortality. Aliment Pharmacol Ther. 2019;50(5):568–79.
Thomson M, Volk M, Kim HM, Piette JD. An automated telephone monitoring system to identify patients with cirrhosis at risk of re‐hospitalization. Dig Dis Sci. 2015;60(12):3563–9.
Lee TC, Kaiser TE, Alloway R, Woodle ES, Edwards MJ, Shah SA. Telemedicine based remote home monitoring after liver transplantation: results of a randomized prospective trial. Ann Surg. 2019;270(3):564–72.
Bloom P, Wang T, Marx M, Tagerman M, Green B, Arvind A, et al. A smartphone app to manage cirrhotic ascites among outpatients: feasibility study. JMIR Med Inform. 2020;8(9):e17770.
Duarte‐Rojo A, Bloomer PM, Rogers RJ, Hassan MA, Dunn MA, Tevar AD, et al. Introducing EL‐FIT (Exercise and Liver FITness): a smartphone app to prehabilitate and monitor liver transplant candidates. Liver Transpl. 2021;27(4):502–12.
Louissaint J, Lok AS, Fortune BE, Tapper EB. Acceptance and use of a smartphone application in cirrhosis. Liver Int. 2020;40(7):1556–63.
Wegermann K, Wilder JM, Parish A, Niedzwiecki D, Gellad ZF, Muir AJ, et al. Racial and socioeconomic disparities in utilization of telehealth in patients with liver disease during COVID‐19. Dig Dis Sci. 2022;67(1):93–9.
Friedberg MW, Schneider EC, Rosenthal MB, Volpp KG, Werner RM. Association between participation in a multipayer medical home intervention and changes in quality, utilization, and costs of care. JAMA. 2014;311(8):815–25.
Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co‐sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528–62.